February 6, 2019

Towards the Early Diagnosis of Alzheimer’s Disease: A New Paradigm for Clinical Benefit

Hybrid 2021 European College of Neuropsychopharmacology (ECNP) Annual Meeting

Unmasking the Clinical Syndrome with Biomarkers

In the next section, Mathieu Ceccaldi, MD, PhD, outlines how biomarkers can improve the diagnostic accuracy of the clinical syndrome. He discusses the current imaging and fluid biomarkers used to detect the pathophysiological hallmarks of AD; the patient case is revisited to provide a diagnosis based on the overall clinical findings.

Key Learning Objectives from Biogen’s ECNP 2021 Symposium:

  • Provide an understanding of the cognitive, functional, and behavioral symptoms of early-stage AD and the range of tools used to assess the clinical syndrome, with a focus on neuropsychiatric measures
  • Outline the utility of imaging and fluid biomarkers as a complement to clinical assessment for enhancing the early detection and diagnosis of AD
  • Highlight the need for a paradigm shift in AD healthcare across Europe, with best practice strategies to optimize detection, diagnosis, and management

Disclosure: All panelists received honoraria from Biogen for participation in this symposium..

Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.